Somatropin: complete guide

Somatropin is recombinant human growth hormone, with labels giving 1987 as its first U.S. approval year. This guide covers its structure, mechanism, uses, trials and warnings.

Complete guide6 min read

Key takeaway

Somatropin labels give 1987 as the initial U.S. approval year. The molecule has 191 amino acids and a molecular weight of about 22,124 daltons. Drugs@FDA shows that FDA deemed the somatropin applications to be biologics license applications on March 23, 2020.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“Somatropin is FDA-approved, and its labels give 1987 as the initial U.S. approval year.” (this article)
ClassGrowth hormone axis
Body systemsEndocrine & metabolism
Studies cited2 in this article · 2 across 1 article on Somatropin
Related productsGHRH analogs and GH secretagogues

Somatropin is recombinant human growth hormone: a 191-amino-acid chain with the same sequence as the hormone made by the pituitary gland. This guide covers its structure, mechanism, FDA-labeled uses, key trials, label warnings and legal status. Sources were checked on November 17, 2026.

Quick answer: Somatropin is a prescription growth hormone made by recombinant DNA technology in bacteria. Its labels cover growth failure and short stature in children with several conditions, plus adult growth hormone deficiency. One brand, Serostim, is labeled for HIV-associated wasting. The Genotropin label has no boxed warning.

Vitrapep does not sell somatropin; this page is a reference summary of published research and regulatory information.

What is somatropin?

Somatropin is the drug name for human growth hormone (GH) made by recombinant DNA technology. The Humatrope label says it is produced “using Escherichia coli.” It adds that “the amino acid sequence is identical to that of human GH of pituitary origin” (Humatrope label, 2025). The Genotropin label gives 191 amino acid residues and a molecular weight of 22,124 daltons (Genotropin label, 2026).

Is it a peptide? Somatropin is one long chain of amino acids, so it is a polypeptide hormone. At 191 amino acids, it is large enough to count as a protein under FDA rules. Federal regulations define a protein as an amino acid polymer “greater than 40 amino acids in size” (21 CFR 600.3). Our peptide vs protein explainer covers that line. PubChem has no compound record for somatropin, so no molecular formula is given here.

Drugs@FDA lists Humatrope (Eli Lilly) with an original approval date of October 16, 1986, while current labels give 1987 as the initial approval year. Its record notes: “This Former NDA Was Deemed To Be a BLA on March 23, 2020” (Drugs@FDA, Humatrope). Genotropin (Pfizer) followed on August 24, 1995 (Drugs@FDA, Genotropin).

Table 1

Somatropin: key facts

Fact Detail
Structure type Single-chain polypeptide of 191 amino acids, identical in sequence to pituitary growth hormone
Class Recombinant human growth hormone (biologic)
Molecular formula No PubChem compound record; labels describe it by amino acid count
Molecular weight 22,124 daltons (Genotropin label); about 22,125 daltons (Humatrope label)
First FDA approval 1987 per current labels; Drugs@FDA lists Humatrope (BLA 019640) as October 16, 1986
Brand names (US) Genotropin, Humatrope, Norditropin, Omnitrope, Zomacton, Serostim

How does somatropin work?

Somatropin acts like the body’s own growth hormone. The Humatrope label states: “Somatropin binds to dimeric GH receptors located within the cell membranes of target tissue cells.” That binding starts signaling inside the cell. The cell then makes GH-dependent proteins, including IGF-1, IGF binding protein 3 and the acid-labile subunit (Humatrope label, 2025).

Some effects are direct and others run through IGF-1. The label lists growth of cartilage cells, glucose release from the liver, protein synthesis and fat breakdown. In children with growth disorders, the Genotropin label says treatment “stimulates linear growth.” In adults with GH deficiency, it describes less fat mass and more lean body mass. Two related drugs work on the same axis from other angles: mecasermin and pegvisomant.

What is somatropin approved for?

Indications differ by brand. The Genotropin label lists these uses:

  • growth failure in children due to inadequate secretion of endogenous growth hormone;
  • growth failure due to Prader-Willi syndrome;
  • growth failure in children born small for gestational age who show no catch-up growth by age 2;
  • growth failure in Turner syndrome;
  • idiopathic short stature; and
  • replacement of endogenous growth hormone in adults with growth hormone deficiency of adult or childhood onset.

Other brands add conditions. Humatrope covers “short stature or growth failure in SHOX deficiency” (Humatrope label, 2025). Norditropin covers “short stature associated with Noonan syndrome” (Norditropin label, 2025). Serostim is labeled for adults with HIV and wasting or cachexia. Its stated aim is “to increase lean body mass and body weight, and improve physical endurance” (Serostim label, 2026).

What did the key trials show?

Adult GH deficiency. An early human trial tested recombinant GH in 24 adults with GH deficiency. It was double-blind and placebo-controlled and ran for six months. Lean body mass rose by an average of 5.5 kg in the treated group, and fat mass fell by 5.7 kg. Neither changed significantly with placebo, and body weight did not change. Basal metabolic rate also rose (Salomon et al., 1989).

Idiopathic short stature. A randomized, double-blind, placebo-controlled human trial enrolled 68 children aged 9 to 16 with marked idiopathic short stature. The primary outcome was adult height. Adult height was available for 33 children. The treated group ended 0.51 standard deviation scores taller than placebo, about 3.7 cm (95% CI, 0.10 to 0.92 SDS). A modified intent-to-treat analysis of 62 children found a similar 3.8 cm effect (Leschek et al., 2004).

What side effects does the label list?

The Genotropin label has no boxed warning. It reports pooled adult trial data from 1,145 adults with GH deficiency. The label states that “the majority of the adverse events consisted of mild to moderate symptoms of fluid retention.” In the double-blind phase, these events were significantly more common than with placebo:

  • peripheral swelling: 17.5% vs 5.1% with placebo;
  • joint pain (arthralgia): 17.3% vs 4.2%; and
  • pain in the arms or legs: 14.7% vs 5.9%.

The label’s warnings cover acute critical illness, Prader-Willi syndrome in children, new or recurrent tumors and impaired glucose tolerance or diabetes. They also cover raised pressure in the skull, severe allergic reactions, fluid retention, low adrenal or thyroid function and pancreatitis. In children, they add slipped capital femoral epiphysis and worsening scoliosis. Contraindications include active malignancy, diabetic retinopathy and closed growth plates in children (Genotropin label, 2026).

What is somatropin’s regulatory status, and how is it used in research?

Somatropin is a prescription biologic in the United States. Drugs@FDA records for Humatrope and Genotropin show both were deemed BLAs on March 23, 2020. DailyMed lists current labels for Genotropin, Humatrope, Norditropin, Omnitrope, Zomacton and Serostim (DailyMed, 2026).

Growth hormone also has its own criminal provision in federal law. Under 21 U.S.C. 333(e), knowingly distributing it for human use outside FDA-authorized treatment on a physician’s order is a crime. It carries up to 5 years in prison. The statute defines human growth hormone as “somatrem, somatropin, or an analogue of either of them” (21 U.S.C. 333). The research summarized here is clinical: human trials in children and adults.

Frequently asked questions about somatropin

Is somatropin a peptide?

It is a polypeptide hormone of 191 amino acids. Because it has more than 40 amino acids, FDA rules classify it as a protein.

Is somatropin the same as natural growth hormone?

Its sequence is the same. The Humatrope label says the sequence is identical to human GH of pituitary origin. It is made in E. coli bacteria.

When was somatropin approved?

Somatropin is FDA-approved, and its labels give 1987 as the initial U.S. approval year. Drugs@FDA lists Humatrope with an original approval date of October 16, 1986.

Does somatropin have a boxed warning?

No. The Genotropin label has no boxed warning. Its warnings include acute critical illness, tumors, glucose problems and raised pressure in the skull.

How is somatropin different from somapacitan?

Somatropin has the natural GH sequence. Somapacitan is a modified GH molecule built to stay in the body longer. Our separate guide covers it.

What to know now

  • Structure: 191-amino-acid recombinant human growth hormone; about 22,124 daltons.
  • Approval: labels give 1987; deemed a biologic on March 23, 2020; prescription only.
  • Mechanism: binds GH receptors and raises IGF-1 and other GH-dependent proteins.
  • Uses: pediatric growth disorders and adult GH deficiency; Serostim covers HIV wasting.
  • Evidence: 5.5 kg more lean mass in adults; 3.7 cm adult height gain in idiopathic short stature.
  • Safety: no boxed warning on Genotropin; fluid retention and joint pain lead the adult list.

What we’re watching

Further somatropin label revisions on DailyMed; Genotropin was last revised in July 2026 and Serostim in September 2026. Related guides: somapacitan, tesamorelin and sermorelin.

More for endocrine & metabolism

All 38 compounds for endocrine & metabolism

Sources: Pfizer Laboratories Div Pfizer Inc 2026, GENOTROPIN (somatropin) prescribing information; Eli Lilly and Company 2025, HUMATROPE (somatropin) prescribing information; Novo Nordisk 2025, NORDITROPIN (somatropin) prescribing information; EMD Serono 2026, SEROSTIM (somatropin) prescribing information; U.S. Food and Drug Administration. Drugs@FDA: BLA 019640 (HUMATROPE) . Retrieved November 17, Drugs@FDA: BLA 019640 (HUMATROPE); U.S. Food and Drug Administration. Drugs@FDA: BLA 020280 (GENOTROPIN) . Retrieved November 17, Drugs@FDA: BLA 020280 (GENOTROPIN); Salomon 1989, The New England Journal of Medicine, 321; Leschek 2004, The Journal of Clinical Endocrinology & Metabolism, 89; U.S. National Library of Medicine 2026, DailyMed SPL listing: somatropin; Legal Information Institute. 21 U.S. Code § 333: Penalties . Cornell Law School. Retrieved November 17, 21 U.S. Code § 333: Penalties; Legal Information Institute. 21 CFR § 600.3: Definitions . Cornell Law School. Retrieved November 17, 21 CFR § 600.3: Definitions. All 11 citations

Back to the research library

References

  1. Pfizer Laboratories Div Pfizer Inc. (2026). GENOTROPIN (somatropin) prescribing information (revised 7/2026). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffebf88b-d257-4542-9808-74d9b7167765
  2. Eli Lilly and Company. (2025). HUMATROPE (somatropin) prescribing information (revised 11/2025). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a774e1ae-3997-49ee-8b0e-99a2b315d409
  3. Novo Nordisk. (2025). NORDITROPIN (somatropin) prescribing information (revised 7/2025). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1058e17c-9261-459c-a3e6-fae38d196c14
  4. EMD Serono, Inc. (2026). SEROSTIM (somatropin) prescribing information (revised 9/2026). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=62b01d29-90f0-45b2-a0c4-3a750ba36c8a
  5. U.S. Food and Drug Administration. Drugs@FDA: BLA 019640 (HUMATROPE). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019640
  6. U.S. Food and Drug Administration. Drugs@FDA: BLA 020280 (GENOTROPIN). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020280
  7. Salomon, F., et al. (1989). The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. The New England Journal of Medicine, 321(26), 1797-1803. https://doi.org/10.1056/NEJM198912283212605
  8. Leschek, E. W., et al. (2004). Effect of growth hormone treatment on adult height in peripubertal children with idiopathic short stature: A randomized, double-blind, placebo-controlled trial. The Journal of Clinical Endocrinology & Metabolism, 89(7), 3140-3148. https://doi.org/10.1210/jc.2003-031457
  9. U.S. National Library of Medicine. (2026). DailyMed SPL listing: somatropin. Retrieved November 17, 2026, from https://dailymed.nlm.nih.gov/dailymed/services/v2/spls.json?drug_name=somatropin
  10. Legal Information Institute. 21 U.S. Code § 333: Penalties. Cornell Law School. Retrieved November 17, 2026, from https://www.law.cornell.edu/uscode/text/21/333
  11. Legal Information Institute. 21 CFR § 600.3: Definitions. Cornell Law School. Retrieved November 17, 2026, from https://www.law.cornell.edu/cfr/text/21/600.3